Eli Lilly to Collaborate with Rigel Pharmaceuticals for $960 Million

The companies will co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.
Posted in US